ASCO 20: update of phase 1 showed that AMG 330 was safe and tolerable in R/R AML patients with CRS as the most frequent expected MOA-based toxicity.
Oral presentation by F. Ravandi et al, ASCO 2020
AMG 330, an anti-CD33 BiTE in R/R AML: FIH study
(oral presentation by F. Ravandi, ASH 2018)
This Phase I Dose Escalation Study of 4-Week Cycles of AMG 330 (2 weeks on/2 weeks off) in R/R AML showed encouraging early evidence of anti-leukemic activity and safety in heavily pre-treated patients with R/R AML.